Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.
6 affiliations
- 1Department of Urological Tumors, Instituto Nacional de Cancerología (INCan), Ciudad de México 14080, Mexico.
- 2Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INNSZ), Ciudad de México 14080, Mexico.
- 3Department of Urology, Hospital Central Militar, Secretaría de la Defensa Nacional, Ciudad de México 11600, Mexico.
- 4MSD, Ciudad de México 01090, Mexico.
- 5MSD, São Paulo 04583-110, Brazil.
- 6TISalud, Ciudad de México 06700, Mexico.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder tumors, yet little is known about how it is managed in Mexico, particularly during prolonged Bacillus Calmette-Guérin (BCG) shortages. This retrospective, multicenter observational study characterized the clinical and histopathological profile, the diagnostic and treatment timelines, and the adherence to guideline-recommended care of patients with NMIBC treated at three tertiary referral hospitals in Mexico City. The records of 221 adults diagnosed between January 2010 and December 2020 were reviewed, and the risk of recurrence or progression was classified according to the European Association of Urology 2019 classification. The median age was 68 years (interquartile range [IQR] 59-75) and the male-to-female ratio was 3:1. Hematuria was the most frequent presenting symptom (83.3%). Three-quarters of patients had T1 tumors, 6.3% had concomitant carcinoma in situ, 84.6% had high-grade tumors, and 92.8% were at high risk of recurrence or progression. The median interval from symptom onset to histopathologic diagnosis was 167 days (IQR 81-329) and varied between centers. After diagnosis, the median time to second-look resection was 67 days (IQR 33.5-112) and to the first BCG instillation 92.5 days (IQR 41.8-165.5). Adjuvant intravesical therapy was administered to 66% of patients, most often BCG, although fewer than half of the BCG-treated patients (45%) completed induction, and 40% of the patients eligible for a second-look transurethral resection did not undergo it. Thirty percent of patients had no documented post-treatment surveillance. These real-world data provide a baseline description of NMIBC care in Mexican tertiary centers and identify specific, measurable gaps that may inform standardization and quality-improvement efforts in resource-constrained settings.
Related
- Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys
- Recorrido y barreras en el acceso a diagnóstico y tratamiento de la enfermedad de Chagas en Argentina: un mapa desde la experiencia de las personas The journey and barriers to accessing diagnosis and treatment for Chagas disease in Argentina: a patient journey map based on people’s experiences Percurso e barreiras no acesso ao diagnóstico e ao tratamento da doença de Chagas na Argentina: um panorama a partir de experiências pessoais
- Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.
- Navigating the current and future perioperative treatment landscape of muscle-invasive bladder cancer (MIBC).
- Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic
BibTeX
@article{scavuzzo2026patient,
title = {{Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.}},
author = {Anna Scavuzzo and Ricardo Alonso Castillejos-Molina and Iván Bravo-Castro and Miguel A Jiménez-Ríos and José G Campos-Salcedo and Miguel A Jiménez-Dávila and Brenda Suaste-Carmona and Lucía E Flores-García and Dominihemberg Ferreira and Victoria Castillo and Gabriela Lugo-Martínez and Francisco T Rodríguez Covarrubias},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100597},
url = {https://europepmc.org/article/MED/42930164},
note = {CC BY},
}
RIS
TY - JOUR
TI - Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.
AU - Anna Scavuzzo
AU - Ricardo Alonso Castillejos-Molina
AU - Iván Bravo-Castro
AU - Miguel A Jiménez-Ríos
AU - José G Campos-Salcedo
AU - Miguel A Jiménez-Dávila
AU - Brenda Suaste-Carmona
AU - Lucía E Flores-García
AU - Dominihemberg Ferreira
AU - Victoria Castillo
AU - Gabriela Lugo-Martínez
AU - Francisco T Rodríguez Covarrubias
PY - 2026
DA - 2026/10/02
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100597
UR - https://europepmc.org/article/MED/42930164
AB - Non-muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder tumors, yet little is known about how it is managed in Mexico, particularly during prolonged Bacillus Calmette-Guérin (BCG) shortages. This retrospective, multicenter observational study characterized the clinical and histopathological profile, the diagnostic and treatment timelines, and the adherence to guideline-recommended care of patients with NMIBC treated at three tertiary referral hospitals in Mexico City. The records of 221 adults diagnosed between January 2010 and December 2020 were reviewed, and the risk of recurrence or progression was classified according to the European Association of Urology 2019 classification. The median age was 68 years (interquartile range [IQR] 59-75) and the male-to-female ratio was 3:1. Hematuria was the most frequent presenting symptom (83.3%). Three-quarters of patients had T1 tumors, 6.3% had concomitant carcinoma in situ, 84.6% had high-grade tumors, and 92.8% were at high risk of recurrence or progression. The median interval from symptom onset to histopathologic diagnosis was 167 days (IQR 81-329) and varied between centers. After diagnosis, the median time to second-look resection was 67 days (IQR 33.5-112) and to the first BCG instillation 92.5 days (IQR 41.8-165.5). Adjuvant intravesical therapy was administered to 66% of patients, most often BCG, although fewer than half of the BCG-treated patients (45%) completed induction, and 40% of the patients eligible for a second-look transurethral resection did not undergo it. Thirty percent of patients had no documented post-treatment surveillance. These real-world data provide a baseline description of NMIBC care in Mexican tertiary centers and identify specific, measurable gaps that may inform standardization and quality-improvement efforts in resource-constrained settings.
SN - 1198-0052
SN - 1718-7729
ER -